Evidence map›Paper›PMID 41635813›Full record

ReviewPeerJ2026

Spotlights on ubiquitin-specific proteases in lung cancer: from multifaceted pathophysiological mechanisms to potential therapeutic targets.

Xiaoyun Shen, Ruoqi Wang, Fei Su, Juanjuan Guo, Da Zhao, Fangyun Yuan, Tao Zhang, Xiaoming Hou

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xiaoyun Shen *Gansu University of Chinese Medicine, First School of Clinical Medicine, Gansu University of Chinese Medicine, Lanzhou, Gansu, China.
Ruoqi Wang *Gansu University of Chinese Medicine, First School of Clinical Medicine, Gansu University of Chinese Medicine, Lanzhou, Gansu, China.
Fei SuDepartment of Oncology, The First Hospital of Lanzhou University, The First Hospital of Lanzhou University, Lanzhou, Gansu, China.
Juanjuan GuoGansu University of Chinese Medicine, First School of Clinical Medicine, Gansu University of Chinese Medicine, Lanzhou, Gansu, China.
Da ZhaoDepartment of Oncology, The First Hospital of Lanzhou University, The First Hospital of Lanzhou University, Lanzhou, Gansu, China.
Fangyun YuanDepartment of Oncology, The First Hospital of Lanzhou University, The First Hospital of Lanzhou University, Lanzhou, Gansu, China.
Tao ZhangDepartment of Oncology, The First Hospital of Lanzhou University, The First Hospital of Lanzhou University, Lanzhou, Gansu, China.
Xiaoming HouGansu University of Chinese Medicine, First School of Clinical Medicine, Gansu University of Chinese Medicine, Lanzhou, Gansu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer ranks as the leading cause of cancer-related mortality worldwide, characterised by complex molecular mechanisms and high therapeutic resistance. Ubiquitin-specific proteases, as core members of the deubiquitinating enzyme family, extensively participate in the initiation, progression, metastasis, and treatment resistance of lung cancer by regulating the stability of key proteins. Recent studies indicate that multiple Ubiquitin-Specific Proteases (USP) family members play pivotal roles in lung cancer: Ubiquitin-Specific Peptidase 7 (USP7) promotes proliferation and osimertinib resistance in non-small cell lung cancer by stabilising proteins such as ERβ, c-Abl, and KRAS; Ubiquitin-Specific Peptidase 9, X-linked (USP9X) mediates radiotherapy resistance by regulating KDM4C and REV1; USP10 influences cellular metabolism and chemotherapy sensitivity

Indexed as

Lung NeoplasmsUbiquitin-Specific ProteasesAnimalsHumansMolecular Targeted TherapySignal TransductionUbiquitin-Specific ProteasesAnd deubiquitinationLung cancerUbiquitin-specific proteases

Identifiers

PMID41635813
PMCPMC12863165

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.